🎉 M&A multiples are live!
Check it out!

Corcept Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Corcept Therapeutics and similar public comparables like Vivoryon Therapeutics, Benevolent AI, and Pharming.

Corcept Therapeutics Overview

About Corcept Therapeutics

Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.


Founded

1998

HQ

United States of America
Employees

500

Website

corcept.com

Financials

LTM Revenue $741M

LTM EBITDA n/a

EV

$6.7B

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Corcept Therapeutics Financials

Corcept Therapeutics has a last 12-month revenue of $741M and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Corcept Therapeutics achieved revenue of $675M and an EBITDA of $138M.

Corcept Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Corcept Therapeutics valuation multiples based on analyst estimates

Corcept Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $482M $675M XXX XXX XXX
Gross Profit $396M $476M XXX XXX XXX
Gross Margin 82% 70% XXX XXX XXX
EBITDA $110M $138M XXX XXX XXX
EBITDA Margin 23% 20% XXX XXX XXX
Net Profit $101M $106M XXX XXX XXX
Net Margin 21% 16% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Corcept Therapeutics Stock Performance

As of April 15, 2025, Corcept Therapeutics's stock price is $67.

Corcept Therapeutics has current market cap of $7.1B, and EV of $6.7B.

See Corcept Therapeutics trading valuation data

Corcept Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$6.7B $7.1B XXX XXX XXX XXX $1.36

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Corcept Therapeutics Valuation Multiples

As of April 15, 2025, Corcept Therapeutics has market cap of $7.1B and EV of $6.7B.

Corcept Therapeutics's trades at 9.1x LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Corcept Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Corcept Therapeutics and 10K+ public comps

Corcept Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $6.7B XXX XXX XXX
EV/Revenue 10.0x XXX XXX XXX
EV/EBITDA 48.7x XXX XXX XXX
P/E 50.4x XXX XXX XXX
P/E/Growth 0.7x XXX XXX XXX
EV/FCF 34.4x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Corcept Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Corcept Therapeutics Valuation Multiples

Corcept Therapeutics's NTM/LTM revenue growth is 33%

Corcept Therapeutics's revenue per employee for the last fiscal year averaged $1.4M, while opex per employee averaged $1.1M for the same period.

Over next 12 months, Corcept Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Corcept Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Corcept Therapeutics and other 10K+ public comps

Corcept Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 40% XXX XXX XXX XXX
EBITDA Margin 20% XXX XXX XXX XXX
EBITDA Growth 26% XXX XXX XXX XXX
Rule of 40 (SaaS-only) 54% XXX XXX XXX XXX
Revenue per Employee $1.4M XXX XXX XXX XXX
Opex per Employee $1.1M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue 37% XXX XXX XXX XXX
Opex to Revenue 78% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Corcept Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Corcept Therapeutics M&A and Investment Activity

Corcept Therapeutics acquired  XXX companies to date.

Last acquisition by Corcept Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Corcept Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Corcept Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Corcept Therapeutics

When was Corcept Therapeutics founded? Corcept Therapeutics was founded in 1998.
Where is Corcept Therapeutics headquartered? Corcept Therapeutics is headquartered in United States of America.
How many employees does Corcept Therapeutics have? As of today, Corcept Therapeutics has 500 employees.
Who is the CEO of Corcept Therapeutics? Corcept Therapeutics's CEO is Dr. Joseph K. Belanoff, M.D..
Is Corcept Therapeutics publicy listed? Yes, Corcept Therapeutics is a public company listed on NAS.
What is the stock symbol of Corcept Therapeutics? Corcept Therapeutics trades under CORT ticker.
When did Corcept Therapeutics go public? Corcept Therapeutics went public in 2004.
Who are competitors of Corcept Therapeutics? Similar companies to Corcept Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Corcept Therapeutics? Corcept Therapeutics's current market cap is $7.1B
What is the current revenue of Corcept Therapeutics? Corcept Therapeutics's last 12-month revenue is $741M.
What is the current EV/Revenue multiple of Corcept Therapeutics? Current revenue multiple of Corcept Therapeutics is 9.1x.
What is the current revenue growth of Corcept Therapeutics? Corcept Therapeutics revenue growth between 2023 and 2024 was 40%.
Is Corcept Therapeutics profitable? Yes, Corcept Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.